About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

The FIGHT-RP1 Study | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT03063021

The FIGHT-RP1 Study

Retinitis Pigmentosa (RP) is a devastating eye disease and at present there are no known treatment options that can alter the rate of vision loss. In a series of studies in animal models, the effects ...

Lead sponsor: Johns Hopkins University•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Johns Hopkins University

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•All subjects must meet the following criteria to be eligible for study entry:
•Signed informed consent and authorization of use and disclosure of protected health information
•Age \>18 years
•Patients diagnosed with RP by the investigators, based on clinical phenotype and diagnostic tests

Exclusion Criteria

•Subjects who meet any of the following criteria will be ineligible for study entry:
•Patients with concurrent retinal pathologies that result in vision loss, including but not limited to retinal vein occlusion, diabetic retinopathy and neovascular age-related macular degeneration. If one eye does not have any retinal pathology other than RP, it may be enrolled in the study.
•Patients with uncontrolled arterial hypertension defined as diastolic blood pressure \> 95 mm Hg or systolic blood pressure \> 160 mm Hg despite medical therapy.

Related studies

Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance

NCT07548944 · Retinitis Pigmentosa (RP), Usher Syndrome, and more

RECRUITINGPhase 3

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

NCT05926583 · Retinitis Pigmentosa

RECRUITINGPhase 2

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

NCT07174726 · X-Linked Retinitis Pigmentosa (XLRP)

Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts Hospital

NCT07292987 · Retinitis Pigmentosa (RP)

RECRUITINGPhase 1/2

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

NCT06789445 · Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 19, 2022Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment30

Start dateFeb 2017

Last updatedSep 19, 2022

Condition

Retinitis Pigmentosa

Locations shown

Wilmer Eye Institute, Johns Hopkins

Baltimore, Maryland

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 19, 2022Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions